Nuvalent Reports 31% Response Rate In Patients With Advanced Form Of Lung Cancer

Why is EU probing Amazon and Microsoft cloud services? How did Cloudflare outage disrupt major websites? Why did Home Depot cut its sales forecast? What caused Meta to win its FTC antitrust case? How will Nvidia's upcoming earnings affect markets? Why is Tesla starting a ride-hailing service in Arizona? What impact will US $1B loan have on Three Mile Island?

Nuvalent Reports 31% Response Rate In Patients With Advanced Form Of Lung Cancer

benzinga.com/news/health-care/25/11/48905746/nuvalent-reports-31-response-rate-in-patients-with-advanced-form-of-lung-cancer

Nuvalent, Inc. (NASDAQ:NUVL) on Monday reported topline results from its ALKOVE-1 Phase 1/2 trial.
The study evaluated neladalkib in tyrosine kinase inhibitor (TKI)-pretreated patients with advanced ALK-positive non-small cell lung cancer (NSCLC). The company said the recommended Phase 2…

This story appeared on benzinga.com, 2025-11-17 18:03:10.